Therefore, these results suggested that the combination therapy with a ROS activated pro-drug, such as A100, and a MAPKi, such as dabrafenib, could represent a potential strategy to treat BRAF-mutant melanoma patients and to overcome drug resistance (Table 1) (240). This evidence concerns the gene BRAF and melanoma.